When: Close >$353.44 with volume >1.3M AND MACD histogram contracting AND RSI >40

Then: Add 10-15%

When: Q3 print constructive with reaction holding above $322

Then: Scale to half position

When: Confirmed retest of $395 with MACD positive cross and RSI >50 for two consecutive sessions

Then: Full position

When: Before Q3 earnings (late October)

Then: Sell ~$347 calls (~5% OTM) / buy ~$320 puts (~4% OTM), 60-90d tenor; execution attestation required in decision log with fill confirmation (Y/N, date, mid-fill)

Maintain current weight; honor 305 stop; scale in with only one-third position on confirmed technical reclaims

• RSI at 27.89 on beta 0.33 name signals institutional selling on fundamental concerns, not macro noise—stock down 16.7% in 42 sessions
• Sequestration chatter back; FY2027 defense budget showing flattening growth; CR risk is real; Polymarket shutdown probability is non-trivial
• 305 stop lacks evidence of holding—if it fails, next support is prior 52-week low at 306.77, then 280s with no nearby support below
• 50 SMA at 364.90 is cherry-picked mean reversion target that stock has not achieved in six weeks; this is a wish, not a plan
• MACD histogram at minus 0.08 can flatten at these levels for weeks before resolving—deceleration is not the same as reversal
• Negative earnings skew argues for smaller position size, not larger—the aggressive analyst has it backwards
• 96% zero Fed cut probability and 6% recession odds are consensus, not alpha—already priced into multiple
• 17.7x forward P/E with 17.8% ROE and 4.4 billion FCF is not a gift—median valuation exists for a reason; market uncertain about FY2027 and beyond
• If wrong at 280, conservative loses 1-2% portfolio value versus aggressive losing 5-7%; variance of aggressive trade is much higher
• Defense has been consensus long for two years; de-rating from 400 to 330 happening because cycle is shifting and easy money made

→ vs aggressive: RSI at 27.89 is not a buy signal on a defensive name—low beta names don't get hit on noise; institutional money is repositioning on fundamental concerns including sequestration risk and FY2027 budget uncertainty

→ vs aggressive: MACD histogram at minus 0.08 is not a 'death rattle'—histogram can flatten at these levels for weeks before resolving; one divergence after five lower highs is hope dressed as a signal

→ vs aggressive: Asymmetry argument uses cherry-picked targets—7.5% downside to 305 is only valid if 305 holds, which is unproven; 50 SMA at 364.90 requires mean reversion that has not occurred in six weeks

→ vs aggressive: Negative earnings skew argues FOR smaller positions, not larger—the aggressive analyst has risk management backwards by advocating loading up ahead of a binary catalyst with asymmetric downside outcomes

→ vs aggressive: 'Gift' framing ignores catalyst risk that is compressing the multiple—buying at discounted P/E during structural uncertainty is value trapping, not value investing

HOLD with three refinements: (1) tighten stop from $305 to $322, (2) compress scale-in from three stages to one-quarter to one-third tranche on 10 EMA reclaim plus MACD bullish crossover, (3) pre-commit earnings decision tree—clean beat adds, messy print exits, in-line holds.

• HOLD is directionally correct—selling a quality compounder at bottom of six-week downtrend with 17.8% ROE, 0.48x net leverage, $4.4B FCF, and structural defense tailwinds invites regret
• Aggressive analyst cherry-picks 2 bullish indicators (RSI 27.89, MACD histogram minus 0.08) while ignoring 5 bearish signals (price below 10 EMA, 50 SMA, 200 SMA; five sequential lower highs; six weeks of higher volume on down days)
• Aggressive analyst's 7.5% risk is fabricated—real risk extends to 280s with no nearby support if $305 fails, closer to 15%
• Aggressive analyst's response to negative earnings skew (lean in with larger position) is overconfidence, not asymmetry
• Conservative analyst incorrectly dismisses momentum deceleration—MACD histogram minus 0.08 with flattening MACD line signals trend exhaustion, not noise
• Conservative analyst's 'macro priced in' argument fails: GD down 16.7% in 42 sessions, trading 10% below 200-day MA, specific fundamentals driving underperformance
• Conservative analyst endorses $305 stop (~4x ATR $6.34), which is arbitrary below 52-week low of $306.77—not statistically defensible
• Tighter stop at $322 (1.5x ATR) aligns with actual volatility behavior rather than narrative support levels
• Scale-in framework (10 EMA at $333.24, 50 SMA at $364.90, $395 retest) is too rigid—trader misses upside if stock gaps on clean Q3 print
• Earnings event requires pre-committed decision tree: clean beat holds above $322 triggers add, messy print below $305 triggers exit, in-line triggers hold and wait for next technical trigger
• Macro is tailwind (zero Fed cuts priced, 6% recession odds, defense budget tailwinds) not catalyst—fundamentals aligned but price action not, confirming HOLD not BUY

→ vs aggressive: Cherry-picks RSI at 27.89 and MACD histogram at minus 0.08 while ignoring five bearish indicators; RSI divergence is single-session noise not institutional accumulation; 7.5% risk is fabricated as real downside extends to 280s (~15%); responding to negative earnings skew by leaning in is overconfidence, not asymmetric thinking

→ vs conservative: Dismisses MACD histogram at minus 0.08 and flattening MACD line as noise when deceleration precedes reversal; 'macro priced in' argument contradicts GD down 16.7% in 42 sessions at 10% below 200-day MA; $305 stop is ~4x ATR (not tight) and chosen for narrative below 52-week low of $306.77 rather than statistical basis; three-stage scale-in (10 EMA at $333.24, 50 SMA at $364.90, $395 retest) leaves trader under-positioned if Q3 gaps up